中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 7
Jul.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(7): 1349-1353

Expression of serum 25-hydroxyvitamin D and its clinical significance in patients with nonalcoholic fatty liver disease and obesity

DOI: 10.12449/JCH240711
  • 1.

    Department of Microbiology and Immunology，Shanxi Medical University，Taiyuan 030001，China

  • 2.

    Department of Clinical Laboratory，Shanxi Bethune Hospital，Shanxi Academy of Medical Sciences，The Third Hospital of Shanxi Medical University，Tongji Shanxi Hospital，Taiyuan 030032，China

Research funding:

Natural Science Foundation of Shanxi Province (202203021211239)

More Information
  • Corresponding author: ZHANG Fan， zhangfan11688@163.com （ORCID： 0009-0001-4718-3591）
  • Received Date: 2023-10-10
  • Accepted Date: 2024-01-12
  • Published Date: 2024-07-25
    Abstract
  •   Objective  To investigate the serum level of 25-hydroxyvitamin D in patients with nonalcoholic fatty liver disease （NAFLD） and obesity， as well as the correlation of 25-hydroxyvitamin D with liver function， blood lipids， and inflammatory indicators.  Methods  A total of 90 patients with NAFLD who attended Shanxi Bethune Hospital from January 2022 to March 2023 were enrolled， and according to the body mass index （BMI）， they were divided into NAFLD+obesity group with 60 patients （BMI≥28 kg/m2） and NAFLD group with 30 patients （BMI<28 kg/m2）； 30 individuals who underwent physical examination during the same period of time were enrolled as control group. Related indications were measured for all three groups， including serum 25-hydroxyvitamin D， liver function parameters （alanine aminotransferase ［ALT］， aspartate aminotransferase ［AST］， alkaline phosphatase ［ALP］， gamma-glutamyl transpeptidase ［GGT］， total bilirubin ［TBil］， and direct bilirubin ［DBil］）， blood lipid parameters （high-density lipoprotein ［HDL］， low-density lipoprotein ［LDL］， total cholesterol ［TC］， and triglyceride ［TG］）， inflammatory indicators （high-sensitivity C-reactive protein ［H-CRP］ and Golgi protein 73 ［GP-73］）， cytokines （interleukin-2 ［IL-2］， interleukin-4 ［IL-4］， interleukin-6 ［IL-6］， interleukin-10 ［IL-10］， interleukin-17 ［IL-17］， interleukin-1β ［IL-1β］， tumor necrosis factor-α ［TNF-α］， and interferon gamma ［IFN-γ］）， and liver/spleen volume ratio. A one-way analysis of variance was used for comparison of normally distributed continuous data between multiple groups， and the least significant difference t-test or the Tamhane’s T2 test was used for further comparison between two groups； the Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between multiple groups and further comparison between two groups. A Pearson or Spearman correlation analysis was performed.  Results  Compared with the control group， the NAFLD+obesity group had significant reductions in 25-hydroxyvitamin D， HDL， cytokines （IL-2， IL-4， IL-10， and IFN-γ）， and liver/spleen volume ratio （all P<0.05）， as well as significant increases in liver function parameters （ALT， AST， ALP， GGT， TBil， and DBil）， blood lipid parameters （LDL， TC， and TG）， inflammatory indicators （H-CRP and GP-73）， and cytokines （IL-1β， IL-17， and TNF-α） （all P<0.05）. There were significant differences between the NAFLD+obesity group and the NAFLD group in all the above indicators except liver/spleen volume ratio and H-CRP （all P<0.05）. The correlation analysis showed that 25-hydroxyvitamin D level was negatively correlated with ALT （r=-0.324， P=0.012）， AST （r=-0.421， P=0.001）， ALP （r=-0.435， P=0.001）， GGT （r=-0.343， P=0.007）， TBil （r=-0.532， P<0.001）， DBil （r=-0.521， P<0.001）， LDL （r=-0.405， P=0.001）， TC （r=-0.466， P<0.001）， TG （r=-0.551， P<0.001）， H-CRP （r=-0.434， P=0.014）， GP-73 （r=-0.421， P=0.001）， IL-1β （r=-0.433， P=0.001）， IL-17 （r=-0.465， P<0.001）， and TNF-α （r=-0.533， P<0.001）， and it was positively correlated with HDL （r=0.632， P<0.001）， IL-2 （r=0.546， P<0.001）， IL-4 （r=0.533， P<0.001）， IL-10 （r=0.456， P<0.001）， and liver/spleen volume ratio （r=0.543， P<0.001）.  Conclusion  Serum 25-hydroxyvitamin D is significantly correlated with liver function parameters， blood lipid parameters， and inflammatory indicators in patients with NAFLD and obesity， and it may alleviate the symptoms of patients with NAFLD and obesity by reducing inflammatory response， which provides new intervention strategies for the treatment of NAFLD.

     

    • FullText(HTML)
  • loading
    • References(18)
  • [1]
    DUAN YM, PAN XF, LUO JY, et al. Association of inflammatory cytokines with non-alcoholic fatty liver disease[J]. Front Immunol, 2022, 13: 880298. DOI: 10.3389/fimmu.2022.880298.
    [2]
    ESTES C, ANSTEE QM, ARIAS-LOSTE MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030[J]. J Hepatol, 2018, 69( 4): 896- 904. DOI: 10.1016/j.jhep.2018.05.036.
    [3]
    BAEKE F, TAKIISHI T, KORF H, et al. Vitamin D: Modulator of the immune system[J]. Curr Opin Pharmacol, 2010, 10( 4): 482- 496. DOI: 10.1016/j.coph.2010.04.001.
    [4]
    FU LK, CUI HM, ZOU CY, et al. Correlation between serum 25(OH) vitamin D and liver fibrosis in nonalcoholic fatty liver disease[J/CD]. Chin J Oper Proced Gen Surg(Electronic Edition), 2019, 13( 6): 603- 605. DOI: 10.3877/cma.j.issn.1674-3946.2019.06.019.

    付丽坤, 崔红梅, 邹春燕, 等. 血清25(OH)维生素D与非酒精性脂肪性肝病肝纤维化的相关性研究[J/CD]. 中华普外科手术学杂志(电子版), 2019, 13( 6): 603- 605. DOI: 10.3877/cma.j.issn.1674-3946.2019.06.019.
    [5]
    China Working Group on Obesity. Guidelines for adult overweight and obesity prevention and control in China(excerpt)[J]. Acta Nutr Sin, 2004, 26( 1): 1- 4. DOI: 10.13325/j.cnki.acta.nutr.sin.2004.01.001.

    中国肥胖问题工作组. 中国成人超重和肥胖症预防与控制指南(节录)[J]. 营养学报, 2004, 26( 1): 1- 4. DOI: 10.13325/j.cnki.acta.nutr.sin.2004.01.001.
    [6]
    National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.

    中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
    [7]
    YUAN S, LARSSON SC. Inverse association between serum 25-hydroxyvitamin D and nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2023, 21( 2): 398- 405. DOI: 10.1016/j.cgh.2022.01.021.
    [8]
    BARCHETTA I, CIMINI FA, CAVALLO MG. Vitamin D and metabolic dysfunction-associated fatty liver disease(MAFLD): An update[J]. Nutrients, 2020, 12( 11): 3302. DOI: 10.3390/nu12113302.
    [9]
    LI HL, DENG QM. The clinical significance of the alteration of serum 25(OH)D levels in obese children with nonalcoholic fatty liver disease[J]. Chin Hepatol, 2023, 28( 7): 810- 813. DOI: 10.3969/j.issn.1008-1704.2023.07.018.

    李洪林, 邓全敏. 肥胖儿童非酒精性脂肪性肝病血清25(OH)D水平变化及临床意义[J]. 肝脏, 2023, 28( 7): 810- 813. DOI: 10.3969/j.issn.1008-1704.2023.07.018.
    [10]
    RAO J, ZHANG R, HUANG XD, et al. Clinical effect of vitamin D combined with silybin capsule in the treatment of non-alcoholic fatty liver disease and its effect on serum plas-minogen activator inhibitor-1 and cathepsin D[J]. Clin J Med Offic, 2023, 51( 6): 582- 586. DOI: 10.16680/j.1671-3826.2023.06.09.

    饶静, 张汝, 黄旭东, 等. 维生素D联合水飞蓟宾胶囊治疗非酒精性脂肪性肝病临床效果及其对血清纤溶酶原激活剂抑制物、组织蛋白酶D影响[J]. 临床军医杂志, 2023, 51( 6): 582- 586. DOI: 10.16680/j.1671-3826.2023.06.09.
    [11]
    JU XL, PEI DM. Relationship between 25 hydroxyvitamin D deficiency and abnormal blood lipid, overweight or obesity[J]. J Clin Med Pract, 2020, 24( 6): 101- 104. DOI: 10.7619/jcmp.202006028.

    鞠香丽, 裴冬梅. 25羟维生素D缺乏与血脂异常及超重/肥胖的关系[J]. 实用临床医药杂志, 2020, 24( 6): 101- 104. DOI: 10.7619/jcmp.202006028.
    [12]
    ELIADES M, SPYROU E. Vitamin D: A new player in non-alcoholic fatty liver disease?[J]. World J Gastroenterol, 2015, 21( 6): 1718- 1727. DOI: 10.3748/wjg.v21.i6.1718.
    [13]
    SHEKA AC, ADEYI O, THOMPSON J, et al. Nonalcoholic steatohepatitis: A review[J]. JAMA, 2020, 323( 12): 1175- 1183. DOI: 10.1001/jama.2020.2298.
    [14]
    ZHANG H, LIU JC. Role of serum Golgi protein 73 in nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2023, 39( 3): 657- 662. DOI: 10.3969/j.issn.1001-5256.2023.03.028.

    张航, 刘近春. 血清高尔基体蛋白73在非酒精性脂肪性肝病中的作用[J]. 临床肝胆病杂志, 2023, 39( 3): 657- 662. DOI: 10.3969/j.issn.1001-5256.2023.03.028.
    [15]
    ZHANG JJ, YU HC, LI Y, et al. Association between serum 25-hydroxy vitamin D concentrations and mortality among individuals with metabolic dysfunction-associated fatty liver disease: A prospective cohort study[J]. Am J Clin Nutr, 2022, 116( 5): 1409- 1417. DOI: 10.1093/ajcn/nqac260.
    [16]
    ZHANG YY, LI JY, NI YQ, et al. Correlational study on the levels of 25-hydroxyvitamin D and non-alcoholic fatty liver disease in type 2 diabetic patients[J]. BMC Endocr Disord, 2021, 21( 1): 100. DOI: 10.1186/s12902-021-00762-1.
    [17]
    CACCIOTTOLO TM, KUMAR A, GODFREY EM, et al. Spleen size does not correlate with histological stage of liver disease in people with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2023, 21( 2): 535- 537. DOI: 10.1016/j.cgh.2022.01.007.
    [18]
    PATEL M, TANN M, LIANGPUNSAKUL S. CT-scan based liver and spleen volume measurement as a prognostic indicator for patients with cirrhosis[J]. Am J Med Sci, 2021, 362( 3): 252- 259. DOI: 10.1016/j.amjms.2020.10.031.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (201) PDF downloads(41) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return